Peptides · Peptide comparison
KPV (Alpha-MSH Fragment) vs Thymosin Beta-4
Anti-inflammatory tripeptide from alpha-melanocyte-stimulating hormone targeting NF-κB and gut inflammation
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Anti-Inflammatory
Gut Health
Healing & Recovery
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical data
Compound specifications
KPV (Alpha-MSH Fragment)
- Molecular formula
- C16H30N4O4
- Molecular weight
- 342.43 Da
- Half-life
- Short peptide half-life; improved by nanoparticle and hydrogel formulations
- Bioavailability
- Oral uptake via PepT1 transporter; enhanced by nanoparticle formulations
- CAS number
- 67727-97-3
Thymosin Beta-4
- Molecular formula
- C212H350N56O78S
- Molecular weight
- 4963
- Half-life
- Dose-dependent (increases with higher doses)
- Bioavailability
- 100% (subcutaneous and intravenous)
- CAS number
- 77591-33-4
Protocols
Dosing compared
KPV (Alpha-MSH Fragment)
Subcutaneous
- 200 mcgOnce daily · 4-6 weeksLower end of the subcutaneous practice range for systemic anti-inflammatory use; KPV is the C-terminal tripeptide of alpha-MSH and acts on NF-kB signaling [3][6].
- 300-500 mcgOnce daily · 4-6 weeksMost commonly used subcutaneous practice dose for systemic/extra-intestinal inflammation; some practitioners escalate toward 500 mcg during acute flares [6].
Oral
- 1000-1500 mcgOnce daily · 4-6 weeksOral route is used for gut-directed effects (e.g., IBD/ulcerative colitis models), taking advantage of PepT1 uptake; preclinical colitis studies support this application, doses are research practice [2][6].
Topical
- 0.01-0.1% cream or serumTwice daily · 7-14 days (acute) up to 4-8 weeks (chronic)Applied as a 0.01-0.1% topical formulation to affected skin for localized inflammation (eczema, rosacea, post-procedure redness); penetration enhancers are often added. Research/practice use [6].
Thymosin Beta-4
Subcutaneous injection
- 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
- 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
- 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Applications
Best suited for
KPV (Alpha-MSH Fragment)
- Inflammatory bowel disease research
- KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on inflammatory bowel disease research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][4].
- Gut anti-inflammatory therapy development
- KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on gut anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][4].
- Skin inflammation and wound healing
- KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on skin inflammation and wound healing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
- Cytokine-mediated inflammation studies
- KPV (Alpha-MSH Fragment) is particularly well-suited for individuals focused on cytokine-mediated inflammation studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
- Post-Surgery Recovery
- Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
- Chronic Wound Management
- Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
- Tissue Regeneration
- Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety profile
Side effects
KPV (Alpha-MSH Fragment)
Common
- Injection Site Reaction
- Mild GI Effects
- Transient Skin Effects
- Mild Immune Modulation
- Peptide Stability Concerns
Uncommon
- Theoretical Immunosuppression
Serious
- Immune Tolerance Development
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research status
Safety & evidence
KPV (Alpha-MSH Fragment)
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- Research compound
- Safety overview
- KPV is a tripeptide fragment of alpha-MSH with excellent tolerability in preclinical models and limited human safety data. The compound shows immunomodulatory properties targeting anti-inflammatory pathways (IL-1 and TNF-alpha suppression) rather than broad immune activation, potentially making it safer for individuals concerned about excessive immune stimulation. Skin darkening and appetite stimulation are documented alpha-MSH effects but less pronounced with the KPV fragment. Safety remains largely determined by route and dose, with cutaneous application showing minimal systemic absorption.
Contraindications
- Not approved for human clinical use
- Unknown interactions with immunosuppressive medications
- Insufficient safety data for pregnancy and lactation
- Potential melanocortin receptor effects in susceptible individuals
Thymosin Beta-4
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Decision guide
Which is right for you?
KPV (Alpha-MSH Fragment)
Choose KPV (Alpha-MSH Fragment) if…
- Inflammatory bowel disease research
- Gut anti-inflammatory therapy development
- Skin inflammation and wound healing
- Cytokine-mediated inflammation studies
Thymosin Beta-4
Choose Thymosin Beta-4 if…
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation